(VIANEWS) – Great Elm Capital Corp. (GECC), Horizon Therapeutics (HZNP), Travelzoo (TZOO) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Great Elm Capital Corp. (GECC)
18% sales growth and 7.78% return on equity
Great Elm Capital Corporation is a business development company which specializes in loan and mezzanine, middle market investments. The fund prefers to invest in media, commercial services and supplies, healthcare, telecommunication services, communications equipment. It typically makes equity investments between $3 million and $10 million in companies with revenues between $3 million and $75 million.
Earnings Per Share
As for profitability, Great Elm Capital Corp. has a trailing twelve months EPS of $-0.3.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.78%.
Volume
Today’s last reported volume for Great Elm Capital Corp. is 34123 which is 16.24% below its average volume of 40741.
Sales Growth
Great Elm Capital Corp.’s sales growth is 42.7% for the present quarter and 18% for the next.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Jun 13, 2023, the estimated forward annual dividend rate is 1.5 and the estimated forward annual dividend yield is 16.03%.
Moving Average
Great Elm Capital Corp.’s value is way higher than its 50-day moving average of $8.12 and higher than its 200-day moving average of $8.75.
2. Horizon Therapeutics (HZNP)
17.6% sales growth and 8.54% return on equity
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.
Earnings Per Share
As for profitability, Horizon Therapeutics has a trailing twelve months EPS of $1.58.
PE Ratio
Horizon Therapeutics has a trailing twelve months price to earnings ratio of 65.98. Meaning, the purchaser of the share is investing $65.98 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.54%.
Moving Average
Horizon Therapeutics’s value is higher than its 50-day moving average of $102.07 and above its 200-day moving average of $103.79.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 6.4% and 33.1%, respectively.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Horizon Therapeutics’s EBITDA is 6.54.
3. Travelzoo (TZOO)
16.9% sales growth and 112.17% return on equity
Travelzoo, an Internet media company, provides travel, entertainment, and local deals from travel and entertainment companies, and local businesses in the Asia Pacific, Europe, and North America. Its publications and products include Travelzoo Website; Travelzoo iPhone and Android apps; Travelzoo Top 20 email newsletter; and Newsflash email alert service. The company also operates the Travelzoo Network, a network of third-party Websites that list travel deals published by the company; and Local Deals and Getaway listings, which allow its members to purchase vouchers for deals from local businesses, such as spas, hotels, and restaurants. It serves airlines, hotels, cruise lines, vacations packagers, tour operators, destinations, car rental companies, travel agents, theater and performing arts groups, restaurants, spas, and activity companies. Travelzoo Inc. was founded in 1998 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, Travelzoo has a trailing twelve months EPS of $0.56.
PE Ratio
Travelzoo has a trailing twelve months price to earnings ratio of 12.5. Meaning, the purchaser of the share is investing $12.5 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 112.17%.
Yearly Top and Bottom Value
Travelzoo’s stock is valued at $7.00 at 01:22 EST, way below its 52-week high of $10.86 and way above its 52-week low of $4.10.
Moving Average
Travelzoo’s value is way under its 50-day moving average of $8.65 and higher than its 200-day moving average of $6.40.
4. iRadimed Corporation (IRMD)
14.4% sales growth and 21.77% return on equity
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.
Earnings Per Share
As for profitability, iRadimed Corporation has a trailing twelve months EPS of $1.14.
PE Ratio
iRadimed Corporation has a trailing twelve months price to earnings ratio of 41.88. Meaning, the purchaser of the share is investing $41.88 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.77%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
iRadimed Corporation’s EBITDA is 9.32.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 24.1% and 9.4%, respectively.
Sales Growth
iRadimed Corporation’s sales growth is 22.4% for the current quarter and 14.4% for the next.
5. Global Self Storage (SELF)
10.7% sales growth and 6.12% return on equity
Global Self Storage is a self-administered and self-managed REIT that owns, operates, manages, acquires, develops and redevelops self-storage properties. The company's self-storage properties are designed to offer affordable, easily accessible and secure storage space for residential and commercial customers. Through its wholly owned subsidiaries, the company owns and/or manages 13 self-storage properties in Connecticut, Illinois, Indiana, New York, Ohio, Pennsylvania, South Carolina, and Oklahoma.
Earnings Per Share
As for profitability, Global Self Storage has a trailing twelve months EPS of $0.25.
PE Ratio
Global Self Storage has a trailing twelve months price to earnings ratio of 20.08. Meaning, the purchaser of the share is investing $20.08 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.12%.
Volume
Today’s last reported volume for Global Self Storage is 24858 which is 33.83% above its average volume of 18574.
Yearly Top and Bottom Value
Global Self Storage’s stock is valued at $5.02 at 01:22 EST, way under its 52-week high of $6.39 and above its 52-week low of $4.75.
6. Acadia Healthcare Company (ACHC)
7.7% sales growth and 9.61% return on equity
Acadia Healthcare Company, Inc. develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, substance abuse facilities, and outpatient behavioral healthcare facilities to serve the behavioral health and recovery needs of communities in the United States and Puerto Rico. The company operates acute inpatient psychiatric facilities, which cares to stabilize patients that are either threat to themselves or 24-hour observation, daily intervention, and monitoring by psychiatrists; and specialty treatment facilities, including residential recovery and eating disorder facilities, and comprehensive treatment centers that provide continuum care for adults with addictive disorders and co-occurring mental disorders. It also provides residential treatment centers, which treat patients with behavioral disorders in a non-hospital setting, including outdoor programs; and offer therapeutic placement for children and adolescents with emotional disorders. As of February 28, 2022, it operated a network of 228 behavioral healthcare facilities with approximately 10,500 beds. Acadia Healthcare Company, Inc. was founded in 2005 and is headquartered in Franklin, Tennessee.
Earnings Per Share
As for profitability, Acadia Healthcare Company has a trailing twelve months EPS of $3.11.
PE Ratio
Acadia Healthcare Company has a trailing twelve months price to earnings ratio of 24.13. Meaning, the purchaser of the share is investing $24.13 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.61%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 12.2%, now sitting on 2.78B for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Acadia Healthcare Company’s EBITDA is 3.
Sales Growth
Acadia Healthcare Company’s sales growth is 9% for the present quarter and 7.7% for the next.
Volume
Today’s last reported volume for Acadia Healthcare Company is 363589 which is 44.15% below its average volume of 651095.
7. FS Bancorp (FSBW)
7.7% sales growth and 14.14% return on equity
FS Bancorp, Inc. operates as a bank holding company for 1st Security Bank of Washington that provides banking and financial services to local families, local and regional businesses, and industry niches. The company operates in two segments, Commercial and Consumer Banking; and Home Lending. It offers various deposit instruments, including checking accounts, money market deposit accounts, savings accounts, and certificates of deposit. The company provides one-to-four-family residential first mortgages, second mortgage/home equity loan products, non-mortgage commercial business loans, commercial real estate loans, and construction and development loans, as well as consumer loans, which primarily include personal lines of credit, credit cards, automobile, direct home improvement, loans on deposit, and recreational loans. As of December 31, 2021, it operated 21 full bank service branches and 10 home loan production offices in suburban communities in the greater Puget Sound area, including Snohomish, King, Pierce, Jefferson, Kitsap, Clallam, Grays Harbor, Thurston, and Lewis counties; and one loan production office in the market area of the Tri-Cities. The company was founded in 1936 and is headquartered in Mountlake Terrace, Washington.
Earnings Per Share
As for profitability, FS Bancorp has a trailing twelve months EPS of $4.23.
PE Ratio
FS Bancorp has a trailing twelve months price to earnings ratio of 7.3. Meaning, the purchaser of the share is investing $7.3 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.14%.
Moving Average
FS Bancorp’s worth is below its 50-day moving average of $31.02 and below its 200-day moving average of $31.84.
Revenue Growth
Year-on-year quarterly revenue growth grew by 31.1%, now sitting on 130.84M for the twelve trailing months.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Aug 8, 2023, the estimated forward annual dividend rate is 1 and the estimated forward annual dividend yield is 3.26%.
